Seattle Genetics Reports Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Wall St rises as softer jobs data calms rate-hike fears
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil falls to four-month low as US, Iran conclude talks in Doha
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Whirlpool to close Mexico plant, expects $165M restructuring cost
- Meta Platforms stock surges 8% on cloud business plans
- Wall Street ends choppy session lower as tech shares drop
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
Needham & Company Reiterates Buy Rating on Seattle Genetics (SGEN)
October 30, 2019 7:51 AM EDTNeedham & Company analyst Chad Messer reiterated a Buy rating and $121.00 price target on Seattle Genetics (NASDAQ: SGEN) following the company's 3Q earnings report. Seattle had several positive data readouts in 3Q including results from enfortumab vedotin (EV) at ESMO and topline pivotal tucatinib... More
H.C. Wainwright Reiterates Buy Rating on Seattle Genetics (SGEN)
October 30, 2019 7:44 AM EDTH.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $140.00 price target on Seattle Genetics (NASDAQ: SGEN). With ongoing clinical momentum and against the backdrop of strong Adcetris sales, Fein believes Seattle Genetics is building a powerful value-driving structure upon its various assets.... More
Seattle Genetics (SGEN) Misses Q3 EPS by 19c, Revenues Beat; Raises FY19 Revenue Outlook
October 29, 2019 4:14 PM EDTSeattle Genetics (NASDAQ: SGEN) reported Q3 EPS of ($0.55), $0.19 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $213.26 million versus the consensus estimate of $211.83 million.
We are executing on our vision of becoming a multi-product global oncology company, recently achieving several important milestones across our late-stage pipeline, said Clay Siegall, Ph.D., President and Chief... More
